Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-18

Clinical Trial Update: Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update reporting results on icatibant for hereditary angioedema, focusing on efficacy, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Firazyr (icatibant)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hereditary Angioedema | Phase 4 | Status: COMPLETED | Results posted: 2016-10-18